Fencopain 50

Rx

Indications

• For the treatment of rheumatoid disease, osteoarthritis, ankylosing spondylitis, musculoskeletal disorders and trauma such as periarthritis, frozen shoulder, bursitis, tendinitis, tenosynovitis, low back pain, sprains and strains.
• Flurbiprofen is also indicated for its analgesic effect in the relief of mild to moderate pain in conditions such as dental pain, post-operative pain, dysmenorrhoea and migraine.

Dosage

• Adults
  150-200 mg/day divided into 2, 3, or 4 doses. In cases of severe symptoms or acute exacerbations, the dose may be increased to a maximum of 300 mg/day, divided into multiple doses.
  For dysmenorrhea, take 100 mg when symptoms appear, then take 50-100 mg (1-2 tablets) every 4-6 hours if needed. The total dose should not exceed 300 mg/day.
• Children
  Fencopain 50 is not recommended for children under 12 years of age.
• Elderly
  Elderly patients have a higher risk of adverse effects. Patients with impaired renal function may experience slower drug elimination.
  Caution should be exercised when using this medication, and the dose should be adjusted accordingly.

Usage

• For oral use, it should be taken with or immediately after meals to minimize gastrointestinal irritation.
• The lowest effective dose should be used for the shortest possible time to control symptoms and reduce the risk of side effects.

• Patients with hypersensitivity (asthma, urticaria or allergic type) to flurbiprofen or to any of the inactive ingredients of the drug.
• Patients who have previously shown hypersensitivity reactions (e.g. asthma, rhinitis, angioedema or urticaria) in response to flurbiprofen, aspirin or other NSAIDs.
• Patients with a history of gastrointestinal bleeding or perforation, related to previous NSAID therapy.
• Patients with active, or history of, ulcerative colitis, Crohn’s disease, recurrent peptic ulceration or gastrointestinal haemorrhage (defined as two or more distinct episodes of proven ulceration or bleeding).
• Patients with severe heart failure, hepatic failure and renal failure.
• During the last trimester of pregnancy
• Children under 12 years of age.

• The risk of cardiovascular thrombosis may occur with this medication, especially with high doses or prolonged use.
• The main adverse effects occur in the gastrointestinal tract. Gastrointestinal ulcers, bleeding, or perforation may occur, sometimes seriously, especially in the elderly. In addition, hypersensitivity reactions, cardiovascular disorders, and worsening of infections have been reported.

Commons

• Gastrointestinal disturbances such as nausea, vomiting, diarrhea, indigestion, abdominal pain, flatulence, constipation, black stools, hematemesis, gastrointestinal bleeding;
• Headache, dizziness;
• Fatigue, malaise, edema;
• Fluid retention;
• Abnormal liver function, prolonged bleeding time.

* Aseptic meningitis (especially in patients with existing autoimmune disorders, such as systemic lupus erythematosus and mixed connective tissue disease) with symptoms of stiff neck, headache, nausea, vomiting, fever or disorientation.

• Concomitant use of flurbiprofen with NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to the potential for synergistic effects.
• Caution should be exercised when using flurbiprofen in patients with a history of gastrointestinal disease (ulcerative colitis, Crohn’s disease) as it may worsen these conditions.
• The risk of gastrointestinal bleeding, ulceration, or perforation is higher with increasing doses of flurbiprofen in patients with a history of ulcers, especially if bleeding or perforation complications occur, and in the elderly.
• Caution is needed in patients taking flurbiprofen concomitantly with drugs that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants like warfarin, selective serotonin reuptake inhibitors, or antiplatelet agents like aspirin. If gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued.
• The drug may reduce prostaglandin synthesis, leading to impaired renal function. Patients with renal impairment, heart failure, hepatic dysfunction, those taking diuretics, or the elderly require monitoring of renal function.
• Patients with a history of hypertension or heart failure should exercise caution due to the risk of fluid retention and edema.
• Patients with mild to moderate hypertension or heart failure should be monitored as edema and fluid retention may occur. High-dose or prolonged use of NSAIDs may increase the risk of arterial thrombosis such as myocardial infarction or stroke.
• Patients with cardiovascular disease or risk factors such as hypertension, dyslipidemia, diabetes mellitus, or smoking should carefully consider long-term use.
• The drug may cause serious skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis, often appearing early in the first month of treatment. Discontinue the drug immediately if rash, mucosal lesions, or signs of hypersensitivity occur.
• Caution should be exercised when initiating treatment in dehydrated patients due to the increased risk of renal impairment.
• The drug may inhibit platelet aggregation and prolong bleeding time. Patients with coagulation disorders should be monitored.
• Patients with systemic lupus erythematosus or mixed connective tissue disease are at risk of aseptic meningitis with manifestations such as stiff neck, headache, nausea, fever, or altered consciousness.
• Systemic NSAIDs may increase the risk of myocardial infarction or stroke, especially with high doses and prolonged use. Regular monitoring and instruction of patients to recognize early signs of abnormalities for timely treatment are necessary.
• The drug contains lactose. Patients with galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not use it.
• Flurbiprofen may reduce fertility in women and is not recommended for women trying to conceive.
• Do not use flurbiprofen during the last trimester of pregnancy.
• Flurbiprofen is not recommended for breastfeeding women.
• Adverse effects such as dizziness, drowsiness, fatigue, and visual disturbances may occur after taking NSAIDs. If affected, patients should not drive or operate machinery.